Multi-modality immunotherapy with programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibition plus tyrosine kinase inhibitors (TKIs) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors have become part of the established therapeutic landscape for multiple tumor types. The gene discussed is PDCD1; the disease is neoplasm.